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Abstract
Background: Depression frequently occurs in the elderly. Its cause is largely unknown, but several
studies point to disturbances of biological rhythmicity. In both normal aging, and depression, the
functioning of the suprachiasmatic nucleus (SCN) is impaired, as evidenced by an increased
prevalence of day-night rhythm perturbations, such as sleeping disorders. Moreover, the inhibitory
SCN neurons on the hypothalamus-pituitary adrenocortical axis (HPA-axis) have decreased activity
and HPA-activity is enhanced, when compared to non-depressed elderly. Using bright light therapy
(BLT) the SCN can be stimulated. In addition, the beneficial effects of BLT on seasonal depression
are well accepted. BLT is a potentially safe, nonexpensive and well accepted treatment option. But
the current literature on BLT for depression is inconclusive.
Methods/Design:  This study aims to show whether BLT can reduce non-seasonal major
depression in elderly patients. Randomized double blind placebo controlled trial in 126 subjects of
60 years and older with a diagnosis of major depressive disorder (MDD, DSM-IV/SCID-I). Subjects
are recruited through referrals of psychiatric outpatient clinics and from case finding from
databases of general practitioners and old-people homes in the Amsterdam region. After inclusion
subjects are randomly allocated to the active (bright blue light) vs. placebo (dim red light) condition
using two Philips Bright Light Energy boxes type HF 3304 per subject, from which the light bulbs
have been covered with bright blue- or dim red light- permitting filters. Patients will be stratified
by use of antidepressants. Prior to treatment a one-week period without light treatment will be
used. At three time points several endocrinological, psychophysiological, psychometrically,
neuropsychological measures are performed: just before the start of light therapy, after completion
of three weeks therapy period, and three weeks thereafter.
Published: 31 July 2008
Trials 2008, 9:48 doi:10.1186/1745-6215-9-48
Received: 21 May 2008
Accepted: 31 July 2008
This article is available from: http://www.trialsjournal.com/content/9/1/48
© 2008 Lieverse et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
Page 2 of 10
(page number not for citation purposes)
Discussion: If BLT reduces nonseasonal depression in elderly patients, then additional lightning
may easily be implemented in the homes of patients to serve as add-on treatment to
antidepressants or as a stand-alone treatment in elderly depressed patients. In addition, if our data
support the role of a dysfunctional biological clock in depressed elderly subjects, such a finding may
guide further development of novel chronobiological oriented treatment strategies.
Trial registration: ClinicalTrials.gov identifier: NCT00332670
Background
Depression frequently occurs in the elderly. Prevalence
figures of late-life depression of clinical relevance vary
between 9% and 18% [1]. The effects of depressive disor-
ders on well-being, self-sufficiency and daily functioning
are enormous and and comparable to those of major
chronic physical illnesses, and have clear economic conse-
quences [1-6].
The cause of depression is unknown. However, the circa-
dian system and a decreased activity of the suprachias-
matic nucleus (SCN), which is known as the 'biological
clock' seems to be involved [7]. The age-dependent
decrease of SCN activity could therefore be a risk factor for
aged people to develop circadian rhythm-dependent per-
turbations and HPA-axis hyperactivity and depressive
symptoms [8]. Disruptions in biological rhythms are
known to be strongly associated with mood disorders.
Indeed some of the major hallmarks of major depressive
disorder (MDD) are abnormal sleep/wake, appetite, and
social rhythms [9-11]. Depression symptoms are also
diurnal with the most severe symptoms occurring typi-
cally in the morning [12], and depression is more preva-
lent in areas of the world that receive little sunlight for
extended periods of time [13]. In addition, nearly all of
the successful treatments for mood disorders seem to
affect circadian rhythms, and it appears that the shifts,
resetting and stabilization of these rhythms produced by
these treatments are important for therapeutic efficacy.
Advantages of light therapy
Patients accept and often prefer non-pharmacological
treatments. The few systematic reports of side-effects sug-
gest it is safe with only few counter indications. Light ther-
apy also provides a viable alternative for patients who
refuse, resist or cannot tolerate medication.
Bright light therapy in Seasonal Major Depression
Bright light therapy (BLT) is considered a well and effec-
tive treatment of first choice for Seasonal Affective Disor-
der (SAD) [14], with an onset of action after only few days
of treatment [15], and with a low side effect profile [16].
Its efficacy in SAD is comparable to that of antidepressant
medication [17].
Bright light therapy in Nonseasonal Major Depression
Trials on light therapy in nonseasonal depression have
been overviewed by Kripke [18], and have been subject of
three systematic reviews [17,19,20]. In short, these over-
views have shown a benefit of light therapy. The Cochrane
meta-analysis [19] which includes studies using light as
an adjunctive treatment to antidepressants and to sleep
deprivation or both, found a modest benefit of light treat-
ment for non-seasonal depression in general, thus con-
firming a therapeutic benefit. An American Psychiatric
Association work group concluded that efficacy appears
equivalent to that of antidepressant drugs [17].
Martiny and others [21] investigated bright light com-
pared with dim red light as adjuvant to 50 mg sertraline in
a large sample (n = 90) of nonseasonal depression (mean
age 45 years) and found response rates of 66,7% v. 40,7%
and remission rates of 41,7% v. 14,8% for bright v. dim
light, statistical significant differences favouring bright
light treatment in clinical rated depression [21] scores and
patient reported symptoms, and well being scales [22].
Goel and colleagues [23] gave 5 weeks morning bright
light therapy (10,000 lux, 1 hour) to outpatients with
chronic major depressive illness of ≥ 2 years who achieved
remission rates of 50%; a control group given low-density
negative air ionization showed only minor improvement.
The Committee on Chronotherapeutics [24] delegated by
the International Society for Affective Disorders (SAD)
concluded that light therapy hastens and potentiates the
antidepressant response as an adjuvant to conventional
antidepressants. Light therapy shows benefit even for
patients with chronic depression of 2 years or more, out-
performing their weak response to drugs. It should be
noted, though, that all available reviews emphasize the
need for further study because of the great diversity of
short-duration study designs and relatively small sample
sizes, all available overviews emphasized the need for fur-
ther studies (e.g. [20,25]).
BLT in geriatric nonseasonals
Most studies in elderly patients focussed on BLT as a ther-
apeutic means to alleviate disruptive and cognitive symp-
toms of senile dementia. Recent reviews on the beneficial
effects of BLT on sleep and behaviour note that the results
of these studies are far from conclusive [26,27] Few empir-Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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ical studies were performed in geriatric depression per se.
A small crossover study (N = 10) in institutionalized
patients with moderate-to-high Geriatric Depression Scale
scores [28] tested morning bright (10,000 lux) versus ver-
sus dim light (300 lux), 30 minutes, 5 days, and obtained
significant mood improvement under the active condi-
tion. However, these patients had no diagnosis of major
depressive disorder. In the tropical climate of Taiwan, a
trial of hospitalized patients with MDD (N = 30) [29]
found alleviation of depressive symptoms after 5 days of
morning light treatment (5000 lux, 50 minutes) in com-
parison with an untreated control group. However, the
largest randomised controlled clinical trial in older
patients (N = 81, 5 weeks) [30] found no significant ben-
efit of bright light (10,000 lux, 1 hour; individualized
according to pre-treatment phase typing into morning,
midday, or evening application) over a 10-lux dim red
control. Thus, results from studies on the effectiveness of
BLT for geriatric depression are not conclusive.
How light therapy may work
The neurobiological effect of light is mediated through
the retina of the eye which is connected to the suprachias-
matic nuclei (SCN) situated just above the chiasmatic
crossing of the optic nerve through the retinohypotha-
lamic tract. The SCN is considered the major circadian
pacemaker in mammals. Neural connections from the
SCN are connected to the pineal gland and by this path-
way the melatonin secretion of the pineal gland can be
suppressed by light [31]. To date, the mood enhancing
mechanism of bright light remains unknown.
Wavelength
There are some indications that certain wavelengths of
light are more effective than others in promoting a thera-
peutic response with the fewest side effects. This could be
due to the ability of certain wavelengths of light to more
effectively control circadian rhythms [32]. Recent studies
have found that light in the blue spectrum (446–477 nm)
outperforms other wavelengths in melatonin suppres-
sion, circadian phase shifting, and antidepressant effects
[33,34].
Ocular safety
Long-term follow-up of patients with cumulative expo-
sure durations up to 1250 h demonstrated the ophthal-
mologic safety of light therapy, at least in patients without
pre-existing ocular abnormalities [35].
Several ways to address the placebo issue have been 
developed
The difficulty of creating a valid placebo condition is one
of the main difficulties in light treatment trials. Eastman
et al [36] and Goël et al [23] used a deactivated air ioniza-
tion generator as a placebo control and checked that the
daily behavioural commitment was equal to the one for
light treatment and that the expectations of the patients
were similar.
In SAD, Lewy et al [37] and Terman et al [38] used credi-
ble placebos by exposing the subjects to bright light at
inappropriate times of the day. However, in nonseasonal
depression, it appears impossible to predetermine an
appropriate or inappropriate (placebo) time for light ses-
sions as long as no single chronobiological phase altera-
tion had been associated with depression. In the future it
may well be possible to overcome this by selection of sub-
groups of chronobiologically homogenous patients or
chronotypes. Only the Loving et al. [30] study phase-
typed elderly nonseasonal depressed patients and individ-
ualized timing of light sessions according to clinical actig-
raphy criteria. However, the effect of light on melatonin
phase appeared to be weak, suggesting low compliance or
increased resistance to light in elderly patients.
Antidepressant medication and bright light
In sum, bright light therapy might offer a safe, non-phar-
macological alternative for elderly patients with a major
depressive disorder. The few systematic reports of side-
effects suggest it is safe with only a few counter indica-
tions. Light therapy may also provide a viable alternative
for patients who refuse, resist or cannot tolerate medica-
tion. Finally, it may hasten and potentiate the antidepres-
sant response when used as an adjuvant to conventional
antidepressants. Therefore, the aims of the current study
were to investigate whether bright light therapy is effective
treatment in elderly outpatients suffering from a nonsea-
sonal depressive disorder, when being used as stand-alone
or as an adjuvans to antidepressive therapy.
Methods and design
General objectives
The purpose of this study is to investigate the following
hypotheses:
1. Treatment with bright light improves mood, sleep, con-
centration and self-sufficiency of elderly depressed sub-
jects. This clinical improvement is accompanied by
decreases in cortisol and increase in melatonin concentra-
tions.
2. The eventual beneficial effect of bright light treatment
can be predicted by the presence of sleep-wake rhythm
disturbances as found using muscle activity registration,
and by cortisol and melatonin concentrations in saliva
and urine over the day and the night.
Design
A scheme-diagram of the trial protocol is presented in fig-
ure 1.Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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Participants
Volunteers are recruited in the Amsterdam region using
four strategies: (1) referrals from several outpatient psy-
chiatry secondary care settings specialized in elderly care
in the Amsterdam region, (2) referrals from general prac-
titioners, (3) advertisements in local newspapers, folders
from 25 apothecaries and waiting rooms of general prac-
titioners, (4) an active case-finding procedure by screen-
ing elderly populations from 16 General Practitioners
Offices using the 15-item version of the Geriatric Depres-
sion Scale (GDS-15, [39]). Subjects with a GDS-15 score
of five or more or with depressive symptoms are inter-
viewed by telephone and/or a live interview to establish
whether they fulfil the eligibility criteria.
Inclusion and exclusion criteria
The inclusion criteria are 60 years or more of age, a pri-
mary diagnosis of Major Depressive Disorder according to
DSM-IV criteria, as assessed with the Structured Clinical
Interview [40] by a trained research physician (RL) or a
specially trained research psychologist.
Candidates are not admitted to the study if any of the fol-
lowing criteria were present: (1) insufficient fluency in
Scheme-diagram of the trial protocol Figure 1
Scheme-diagram of the trial protocol.Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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Dutch, (2) living outside the Amsterdam region, insuffi-
cient address for follow-up, or unwillingness to return for
follow-up, (3) light treatment in the past, (4) history of
light-indicated migraine or epilepsy, (5) presence of phys-
ical illnesses that require urgent specialized treatment
(e.g. untreated diabetes, malignancies, chronic infections,
thyroid problems, eye diseases (glaucoma, cataract) for
which surgery is scheduled in near future), (6) the pres-
ence of other major axis-I disorders like bipolar disorder,
dementia, delirium, all psychotic disorders, PTSD, a
recent history of a suicide attempt, the presence of the
DSM-IV Seasonal Pattern specifier, (7) diseases that could
interfere with HPA-axis functioning, or (8) diseases or
medication that could elevate the risk of light-therapy
associated side effects (e.g. progressive eye diseases, senile
macula degeneration, Lupus, tricyclic antidepressants, tet-
racyclic antibiotics), (9) current drug or alcohol abuse less
than 3 months before the study, (10) any drugs (e.g. cor-
ticosteroids, cyclosporin A) known to interfere with endo-
crine function. Also excluded were all subjects who were
taking (11) SSRIs or SNRIs shorter than 2 months.
Interventions
We chose to use dim red light as a placebo, reasoning that
because the red part of the spectrum is biologically rela-
tively inactive, there would be no substantial effect.
Another advantage of red light as placebo is that it induces
very strong positive expectations quite comparable to
those of bright white light [41,30].
Patients receive either early morning bright blue light or
early morning dim red light. Portable light boxes are used
with a fixed (non-tuneable) light-intensity (Philips Bright
Light Energy® boxes type HF 3304). Mistblue filters (Leev-
ellen Lee 061) are built in to arrange the active bright-light
condition. Blood-red filters (Leevellen Lee 789) are built
in for the placebo dim-red light condition. On the outside
of the boxes no difference is observable between the two
conditions. Emitted light spectra and intensities are quan-
tified using a lux meter at 40 cm from two light boxes.
Bright light consists of approximately 10.000 lux. Dim red
light consists of less than 50 lux. Environmental light in
the subject's home at the designated sitting place of light
therapy is measured at the start of the light therapy using
a lux-meter.
We offer a 3 week treatment period of 1 hour of light ther-
apy each day. At installation of the light devices, patients
choose a 3-week-lasting fixed starting time anchored
within 1 hour from their habitual wake-up time. Clock-
programmable power supply of two light-boxes is set to
switch 'on' at that time-point every day during the 3-week
period and 'off' after one hour.
Compliance
Compliance to light therapy is retrospectively measured
by lux-meters that were built in the wrist-worn actimeters
patients wear during the entire protocol. Subjects are
instructed by a protocol-blinded instructor to sit at their
table, with the light boxes put at a distance of approxi-
mately 40 cm from the eyes. During therapy, subjects sit
at the table to have breakfast or do some reading (e.g.
news paper). Participants will be asked to note their com-
pliance in their trial-diaries.
Sample size
Martiny et al. [21] found a moderate effect size (ES>0,50
maximum 0,66) for bright light treated group in compar-
ison with dim light treated group on both self-assessment
and observer rating scales in patients with a high preva-
lence of melancholic depression. Based on the literature
on the expected response rate, and using conventional val-
ues for α (0.05) and β (0.80), and two-tailed tests with
equal groups, the sample size aimed for in the current
study is 63 patients per arm [42].
Randomization
Randomisation was prepared by an independent
researcher (BU) using a computer generated table, block-
ing in subsets of 10, transcribed to closed envelope mes-
sages. Stratification is applied for use antidepressant
medication (SSRIs and SRNIs were allowed). After inclu-
sion the researcher sends an email with name, contact
information and condition i.e. AD+ or AD-) to one of our
two specially trained protocol-blinded instructors. As a
check the instructor writes the allocated condition onto a
paper which is kept in a special envelope in the same box
with the closed envelopes.
Blinding
The study is presented to the patients to study whether
light therapy would be a beneficial treatment modality for
major depressive disorder. The blue light and red light
conditions are presented to study whether a specific part
of the light spectrum would be more effective than
another.
Light treatment is blinded to the investigators as the lamps
are delivered at the patient's homes by a specially trained
protocol blinded instructor, so the instructors are led to
believe that the blue and red light conditions are to study
which part of the spectrum worked better than the other.
The patients are asked not to refer any details of their con-
dition to the investigators as this would harm the study.
When patients however do reveal their condition, the
researcher will be replaced immediately by another
researcher to perform psychometrical interviewing and
ratings.Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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To evaluate the blinding procedure, and in order to assess
participants' general expectations for light therapy and
their specific expectations in respect to their allocated
light boxes, we measure expectations before the light box
was installed using a four item expectations question-
naire. Briefly, participants rate, on a 7-points scale (1 =
feeling much better, 2 = feeling definitely better, 3 = feel-
ing slightly better, 4 = no change, 5 = feeling slightly
worse, 6 = feeling definitely worse, 7 = feeling much
worse), how they thought light therapy would improve
their symptoms. We use four questions to be rated: (1) To
what extent do you expect your problems will improve
without treatment? (2) To what extent do you expect your
problems will improve with light treatment? (3) To what
extent do you expect your problems will improve with the
blue light treatment? (4) To what extent do you expect
your problems will improve with the red light treatment?
Statistical analysis
Data will be analyzed using SPSS 16.0. Analyses are per-
formed using intention-to-treat principles. Therefore,
drop-outs are distinguished into 'drop-outs before T1
assessment' and 'drop-outs after T1 assessment'. When
only a randomisation assessment (T0) is available, sub-
jects are considered lost to follow-up. For 'drop-outs after
T1 assessment' the principle of LOCF (last observation
carried forward) will be used. For sensitivity analysis, the
more conservative LOCF variant will be calculated where
T0-data will be carried forward, and a completers analysis
will be performed.
Baseline characteristics across the treatment groups are
compared using analysis of variance (ANOVA) and χ2-sta-
tistics.
As the primary analysis efficacy of treatment is tested by
performing a repeated measures analysis of variance
(RMANOVA) on HADRS-17 scores at T0, T1 and T2. To
control for possible difference in baseline severity scores
baseline values for HADRS-17 are used as covariates.
Repeated contrasts are applied to compare effects in the
treatment period with effects after the treatment period.
As secondary analyses efficacy of treatment is tested by
performing RMANOVA on the other depression symptom
scales (SIGH-SAD scores, HAM-D6, MADRS-scores). As
tertiary analyses depression outcome measures are dichot-
omised to responders and non-responders, where
response is defined as a decrease of ≥ 50% on the HADRS-
17, HAM-D6, SIGH-SAD and MADRS scales. Responder
rates will also be presented as odd's ratios and NNT's.
Approval
The current study is executed in accordance with the prin-
ciples laid down in the Helsinki Declaration [43]. Partici-
pation in the study is voluntary, and written informed
consent is obtained. The patients are explicitly informed
of the fact that they can withdraw their consent to partici-
pate at any time, without specification of reasons and with
no negative consequences with regard to their future med-
ical treatment. Patients who wish to withdraw from the
study will receive care as usual. Approvals were obtained
by the Dutch authorities and the medical ethical commit-
tee of GGZ Nederland.
Primary Outcome measure
Depression severity is assessed by a trained research phy-
sician and qualified research psychologists (MN, RdV)
using the Montgomery-Åsberg Depression Rating Scale
(MADRS) [44], the combined 21-item Hamilton and 8-
item atypical symptom scales of the Structured Interview
Guide for the Hamilton Depression Rating Scale – Sea-
sonal Affective Disorder Version (SIGH-SAD) [45], which
although originally designed for SAD studies is equally
applicable for assessment of nonseasonal depression with
atypical features (as in the present study). The Hamilton
and atypical symptom subscales of the SIGH-SAD can be
analyzed separately or in combination [46]. The primary
outcome measure is depression ratings using the HADRS-
17 scale. Response is defined as a 50% reduction in
depressive symptoms, on the HADRS-17 scale at T1 and
T2. Specially trained clinical research staff conducts the
interview.
Secondary Outcome measures
Secondary outcome measures are clinical response (i.e.
50% reduction in depressive symptoms) on the 29-items
SIGH-SAD, the Atypical-8 subset from the SIGH-SAD, the
HAMD-6 depression core features subscore, and the
MADRS. Specially trained clinical research staff conducted
the interviews.
Adverse effects
At each visit and 4 additional times, subjects are systemat-
ically asked about possible side effects by the blind raters:
early morning awakening, headache, agitation, drowsi-
ness, irritability, tight muscles, nervousness, anxiety,
tremor, dizziness, fatigue nausea, diarrhoea, dry mouth,
anorexia, dyspepsia, constipation, excessive sweating,
rash, asthenia, viral infection, upper respiratory infection,
flulike syndrome, nasal congestion and hot flushes [47].
Each item is rated as absent, mild, moderate or severe. The
subjects were instructed to report any side effects that
could have jeopardized the blindness of the raters (such as
eye strain, a side effect characteristic of bright light) to a
nonblind research assistant who simply tabulated these
side effects.
Endocrine measures
1. Activity of the HPA-axis was assessed by free cortisol
assessment using 8 saliva samples per respondent perTrials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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time. As a measure of a natural "stress" response of the
HPA-axis, the morning cortisol awakening response
(CAR) is assessed by taking saliva samples at T0, T1 and T2
(at get-up time plus 30 minutes, plus 60 minutes, plus 90
minutes, plus 120 minutes), and the cortisol evening
curve (bedtime minus 4 hours, minus 3 hours, minus 2
hours, minus 1 hour). Saliva samples are collected using
cotton swaps (Salivettes, Sarstedt, Germany). Subjects are
instructed to be seated during the last 15 minutes before
saliva collection. During the entire sampling period, sub-
jects can watch TV or perform leisure activities. Eating and
drinking (with the exception of coffee, tea, chocolate, and
bananas), and smoking will be permitted. Saliva contain-
ers are kept in the patient's refrigerators and are to be col-
lected by the psychometrist the next day after
psychometry, which are delivered to the clinical labwhere
it is spinned down and stored at -85°C. Cortisol will be
assayed on an Elecsys using a standard cortisol kit
(Roche). Saliva samples are frozen in order to do all meas-
urements at once.
2. To determine a patients circadian phase position the
Dim Light Melatonin Onset (DLMO; the time point when
melatonin secretion rises over a predefined threshold in
the evening, under experimental dim light conditions)
will be calculated after measuring the melatonin evening
curve using measurements in saliva samples (bedtime
minus 4 hours, minus 3 hours, minus 2 hours, minus 1
hour) at T0, T1 and T2.
3. Total cortisol excretion at T0, T1 and T2 will be deter-
mined using 24-hour urine collections. Collections are
carried in the participants' own homes, following proce-
dures provided through detailed written and verbal
instructions. Urine is collected for 24 hours after the first
voided urine following awakening, and included the first
voided urine on the following day. Three liter polyethyl-
ene collection bottles were used. The completeness of data
collection is ascertained by measurements of the 24-hr
urine volume and creatinine excretion. Only participants
demonstrating good compliance, using this quality con-
trol step, will be included in the analyses. The urinary free
cortisol (UFC) will be determined by radioimmunoassay
using a commercially available (Coat A Coat, Diagnostic
Product Corporation (DPC), Los Angeles USA) antibody
specific for cortisol and I-125-labeled antigen. Urinary
measurements are performed by the laboratory at arrival.
Actigraphy
Before, during treatment and three weeks after treatment
circadian rest-activity will be measured using actography.
The small (57 × 46 × 22 mm) and light-weight (70 g)
wrist-worn actigraph, which senses movement-induced
accelerations, as described elsewhere [48].
Estimates of sleep parameters are obtained using the vali-
dated Sleepwatch Analysis Software 201 (Cambridge Neu-
rotechnology Ltd., Cambridge, UK). The software
automatically calculates Sleepstart and Sleepend, which
are limited to occur at any time between the habitual Bed
Time and Get Up Time as read from the sleep logs and
entered into the software; Assumed sleep (the difference
between Sleep End and Sleep Start), Actual Sleep time
(amount of sleep determined by the algorithm and equiv-
alent to assumed sleep minus wake time. We defined
Sleep Efficiency bas the percentage of actual sleep time
between sleep onset and final awakening, excluding sleep
onset latency. Mean Activity scores are average activity
scores in those epochs where scores of greater than zero
are recorded during the assumed sleep period.
Circadian rest activity pattern is quantified using several
actimetric variables. The Interdaily Stability (IS) gives an
indication of of the stability of the 24-hour rest activity
pattern over days. The intradaily variability (IV) gives an
indication of the fragmentation of the rhythm, by quanti-
fying the number and strength of transitions between
periods of rest and activity. L5 quantifies the activity level
during the core sleep period. M10 describes the daytime
activity level. AMP is an absolute amplitude measure and
calculated as the difference between M10 and L5. The rel-
ative amplitude (RA) is calculated by dividing AMP by the
sum of L5 and M10 [48,49].
Sleep analysis measures
Subjective sleep quality is scored using the Pittsburgh
Sleep Quality Inventory (PSQI) at T0, T1 and T2 [50]. The
PSQI is a validated self-rated questionnaire which assesses
sleep quality and disturbances. Nineteen individual items
generate seven "component" scores: subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbances, use of sleeping medication, and day-
time dysfunction [50]. PSQI-scores can be dichotomized
as follows: PSQI >/= 5 indicate poor sleep, if PSQI <5 indi-
cates good sleep.
Circadian rhythm measures
An abbreviated version of the Social Rhythm Metric SRM-
17 [51], the SRM-5 [52] was translated back and forth as
there was no validated Dutch translation available. It will
be used to quantify the daily rhythms of life or daily life-
style regularity. These items are: (1) Get out of bed, (2)
First contact with another person, (3) Start work, house-
work or volunteer activities, (4) Have dinner, and (5) Go
to (bed) [52]. From this diary a weekly SRM-score can be
measured, which is a validated measure of lifestyle regu-
larity, yielding the scores of one to three weeks before
treatment, the three treatment weeks and scores from the
three weeks after treatment.Trials 2008, 9:48 http://www.trialsjournal.com/content/9/1/48
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Neuropsychological tests
At T0, T1 and T2 participants will do neuropsychological
tests addressing working memory, using the digit-span
forward and the digit span backward, learning and mem-
ory using the Rivermead stories immediate and delayed
recall, and verbal fluency using animals, insects and occu-
pations.
Questionnaires
Details about the social support is measured using Social
Support Questionnaire (SSQ) [53], at T0, T1 and T2; The
SSQ has 41 items on social support interactions, 41 items
on social support discrepancies and 7 items on negative
interactions. It focuses on seven domains of social sup-
port: emotional Support (four items, refer to the emo-
tional support of everyday life, like showing affection),
social support by problems (eight items, contains items
like cheering and backing up), informative support (four
items, refers to information about one's behaviour like
making the subject understand why something they did
was wrong or making clear what is expected of him-her),
instrumental Support (seven items, refers to financial and
material support, like helping with practical matters, e.g.
shopping or lending small things or Money), Social Com-
panionship scale (five items, are inviting the subject for
dinner or a party and calling him/her up for a chat),
Esteem Support (six items, refer to being valuated by oth-
ers, with items like asking advice or showing confidence).
In order to measure self-sufficiency we chose to use the
MOS-short form General Health Survey (SF-20; abbrevi-
ated form of the RAND-36) [54]. De SF-20, like RAND-36,
is a multi-dimensional instrument to measure general
health. The SF-20 is shorter than RAND-36 and aims on
different aspects of health, e.g. the time of certain health
related impairments. In Groningen SF-20 is widely used
in large studies among elderly people. It contains scales
for physical, social functioning, role impairments due to
physical or emotional problems, mental health, energy,
pain and general perception of health [54].
To additionally measure both the ADL and instrumental
ADL disability with respect to the aid and services pro-
vided by professional home help and district nursing
agencies we will use the Groningen Activiteiten Restric-
tion Scale (GARS; Kempen et al 1993).
The general self-efficacy was measured with the Dutch ver-
sion of the General Self-Efficacy Scale (GSES) the Alge-
mene Competentie Schaal (ALCOS) [55]. The ALCOS-12
as well as the subscales have earlier been shown to be
moderately reliable and valid instrument to measure
(aspects of) generalized expectations of self-efficacy.
A Dutch version of the Philadelphia Geriatric Center
Morale Scale [56] is used to measure well-being and life-
satisfaction at T0, T1 and T2.
Neuroimaging
A subset of consecutively included participants is invited
for 1,5 Tesla MR-scanning at T0 and after therapy at T1.
Scan protocols consist of structural MPRAGE/T1- and T2
weighted magnetic resonance scans of the brain, func-
tional-MRI scans using encoding, facial recognition task
and working memory tasks (N-back). In addition, adrenal
volumetry is performed using abdominal MPRAGE of
adrenals.
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